Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Julia Alten

Predictive Value of MRD in Ph+ ALL Treated With Imatinib in the EsPhALL Study, Based on IG/TR and BCR/ABL1 Methodologies

Haematologica

Hematology

2017

English

Related publications

BCR-ABL1-independent PI3Kinase Activation Causing Imatinib-Resistance

Journal of Hematology and Oncology

English

BCR-ABL1 and Beyond

English

BCR-ABL1 Mutations in Patients With Imatinib-Resistant Philadelphia Chromosome-Positive Leukemia by Use of the PCR-Invader Assay

English

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib

BioResearch Open Access

English

In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Ph+ ALL in First Complete Remission?

Biology of Blood and Marrow Transplantation

Transplantation

Hematology

2018

English

Clinical and Genetic Studies of ETV6/ABL1-positive Chronic Myeloid Leukaemia in Blast Crisis Treated With Imatinib Mesylate

British Journal of Haematology

Hematology

2003

English

The Use of Imatinib Resistance Mutation Analysis to Direct Therapy in Philadelphia Chromosome/BCR-Abl1 Positive Chronic Myeloid Leukaemia Patients Failing Imatinib Treatment, in Patan Hospital, Nepal

British Journal of Haematology

Hematology

2017

English

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Frontiers in Cardiovascular Medicine

Cardiovascular Medicine

Cardiology

2018

English

Monitoring of Minimal Residual Disease (MRD) Is Useful to Predict Prognosis of Adult Patients With Ph-Negative ALL: Results of a Prospective Study (ALL MRD2002 Study)

Journal of Hematology and Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Julia Alten

Predictive Value of MRD in Ph+ ALL Treated With Imatinib in the EsPhALL Study, Based on IG/TR and BCR/ABL1 Methodologies

Related publications

BCR-ABL1-independent PI3Kinase Activation Causing Imatinib-Resistance

BCR-ABL1 and Beyond

BCR-ABL1 Mutations in Patients With Imatinib-Resistant Philadelphia Chromosome-Positive Leukemia by Use of the PCR-Invader Assay

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib

In the Era of BCR-ABL1 Inhibitors, Are We Closing the Survival Gap Between Allogeneic Hematopoietic Cell Transplantation and Chemotherapy for Ph+ ALL in First Complete Remission?

Clinical and Genetic Studies of ETV6/ABL1-positive Chronic Myeloid Leukaemia in Blast Crisis Treated With Imatinib Mesylate

The Use of Imatinib Resistance Mutation Analysis to Direct Therapy in Philadelphia Chromosome/BCR-Abl1 Positive Chronic Myeloid Leukaemia Patients Failing Imatinib Treatment, in Patan Hospital, Nepal

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Monitoring of Minimal Residual Disease (MRD) Is Useful to Predict Prognosis of Adult Patients With Ph-Negative ALL: Results of a Prospective Study (ALL MRD2002 Study)